Connect with us


Linneo wipes out the red numbers with its first medical cannabis harvest

In 2019, Linneo received two capital injections of $2.1 million and $14 million (€1.8 and €12 million) from its shareholders, which helps to address any short-term liquidity needs caused by the Coronavirus pandemic. This summer, Linneo received the first license to export cannabis to Germany, a positive thing for the company’s further development.



The company of Juan Abelló, head of Torreal, dedicated to the production of cannabis for medical use -Linneo Health- is already beginning to have its first results on the table. The company has operational crops in Castilla La-Mancha and Murcia and it is the latter that have been harvested first, as this is the region where the bulk of the company’s land is registered. At the moment, there is a negative balance in its profit and loss account for the financial year 2019, which amounts to $7.45 million (€6.4 million) in red figures.

But you have to look at that data with a magnifying glass because the company is in the middle of an investment process and COVID-19. The company detailed that, although the pandemic has not influenced a drop in Linneo’s activity to ensure liquidity, they have requested a loan of $11.6 million (€10 million) with Santander, they have a line of credit with Bankia, and the contributions of the partners. From this forecast and from the strong initial investment these possible numbers are in the red zone.

Read more about the cannabis company Linneo and find the latest cannabis news in the world with the mobile app.

The company does not have anything in ownership. Both the land and the offices in Madrid are rented, contracts that are extended as the possibilities of the company grow. One of Linneo’s greatest assets is having been the first company in the country to obtain a license from the Spanish Agency for Medicines, an asset valued at $10.9 million (€9.4 million), as well as contractual rights for the supply of the product valued at $3.7 million (€3.2 million).

Although Linneo is not the only Spanish company with a license (there are also the Alicante companies Carfina and Medalchemy and the Madrid company Olis4cure), experts in the sector predict that Abello will be the company that will position itself at the head of the sector. Therefore, it is a temporary negative balance, since the company has all the cards to lead the sector in Spain and bid for the top positions at an international level. 

First license to export cannabis to Germany

This operation in 2018 prompted Torreal and GHO to bring Linneo to market. Alcaliber was the first company in Spain to obtain in 2016 the license from the Spanish Agency of Medicines and Health Products to grow and sell medical cannabis in Spain, a license that was transferred to Linneo after the company was founded.

In 2019, Linneo received two capital injections of $2.1 million and $14 million (€1.8 and €12 million) from its shareholders, which helps to address any short-term liquidity needs caused by the Coronavirus pandemic. This summer, Linneo received the first license to export cannabis to Germany, a country where this product has a wide potential, or so the data indicated. 

According to the report of the consulting firm Prohibition Partners, the cannabis sector will move a total of $18.8 billion (€16.2 billion) in Germany within 10 years: $8.96 billion (€7.7 billion) for medical purposes and $9.9 billion (€8.5 billion) for recreational purposes. It is expected that this export route to the domains of Angela Merkel will be very good for the company.


(Featured image by Tobias Leznem via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in LA INFORMAC!ON, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Valerie Harrison is a mom of two who likes reporting about the world of finance. She learned about the value of investing at a young age upon taking over her family's textile business when she was just a teenager. Valerie's passion for writing can be traced back to working with an editorial team at her corporate job, where she spent significant time working on market analysis and stock market predictions. Her portfolio includes real estate funds, government bonds, and equities in emerging markets such as cannabis, artificial intelligence, and cryptocurrencies.